Selinexor in Combination With MTX+Ritu to Treat R/R CNSL

This is a single-arm and open-label study to explore X+MTX+Ritu (ATG-010, Methotrexate, Rituximab) regimen in Relapse refractory PCNSL patients. Approximately 30 patients will be enrolled in the study. In dose escalation phase, patients with Relapse refractory PCNSL will be treated with X+MTX+Ritu regimen and escalating doses of oral ATG-010 weekly in a 3+3 design. Then a phase 2 expansion at the recommended dose level based on phase 1b trial will be conducted to evaluate the efficacy, safety and tolerability.

Trial Details

NCT ID
NCT05698147
Phase
PHASE1 / PHASE2
Sponsor
Tong Chen, MD
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Selinexor
  • Rituximab
  • Methotrexate
Locations (sample)
  • Hefei, Anhui, China|31.86389,117.28083
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Zhengzhou, Henan, China|34.75778,113.64861
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Patients must meet all of the following inclusion criteria to be eligible to enroll in this study:
  • Participants must be able to understand and be willing to sign a written informed consent document.
  • Men and woman who are 18-75 years old on the day of consenting to the study.
  • Histologically documented PCNSL and SCNSL secondary to histologically documented systemic diffuse large B-cell lymphoma (DLBCL).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →